NCT01586156View on ClinicalTrials.gov

PAHTCH Pulmonary Arterial Hypertension Treatment With Carvedilol for Heart Failure (Carvedilol)

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions
Pulmonary Hypertension
Interventions
DRUG

Carvedilol

Group 1 will receive 3.125mg carvedilol twice daily for six months.Group 2 will receive carvedilol in a dose escalation scheme.

DRUG

placebo

Placebo will be taken twice daily for 6 months

Trial Locations (1)

44195

Cleveland Clinic, Cleveland

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

The Cleveland Clinic

OTHER

NCT01586156 - PAHTCH Pulmonary Arterial Hypertension Treatment With Carvedilol for Heart Failure (Carvedilol) | Biotech Hunter | Biotech Hunter